Evogene earnings beat, revenue fell short of estimates

Investing.com – Evogene (NASDAQ: ) reported second quarter EPS of $-0.170, better than the analyst estimate of $-0.180. Revenue for the quarter came in at $654K versus the consensus estimate of $885K.

Evogene’s stock price closed at $0.780. It is up 30.000% in the last 3 months and down -36.690% in the last 12 months.

Evogene saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Evogene’s stock price’s past reactions to earnings here.

According to InvestingPro, Evogene’s Financial Health score is “fair performance”.

Check out Evogene’s , and Evogene’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar